Endogenous interferon (IFN) in patients with acute hepatitis B

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Acute viral hepatitis B is a significant global health concern.
• Interferon plays a crucial role in the innate immune response against viral infections.
• Understanding interferon dynamics in hepatitis B is vital for therapeutic strategies.

Purpose of the Study:

• To investigate the occurrence and antiviral activity of serum interferon in patients with acute viral hepatitis B.
• To quantify the prevalence of detectable serum interferon during the early stages of the disease.

Main Methods:

• Serum samples were collected from 39 patients diagnosed with acute viral hepatitis B.
• Antiviral activity was assessed by measuring the inhibition of cytopathic effect (CPE) caused by vesicular stomatitis virus on MDBK cells.
• Interferon levels were quantified using a standard bioassay.

Main Results:

• Only 5 out of 39 patients (12.8%) exhibited detectable serum interferon levels within the first week of hospitalization.
• The antiviral activity of the detected interferon was generally low, ranging from 5 to 10 IU/ml.
• The majority of patients with acute viral hepatitis B did not show significant serum interferon presence early in the disease course.

Conclusions:

• Serum interferon is infrequently detected in the early phase of acute viral hepatitis B.
• The low levels of antiviral activity suggest a limited role for endogenous interferon in controlling viral replication during this period.
• Further research is warranted to explore the implications of these findings for hepatitis B management.